Nindanix (Nintedanib)

Nindanix is indicated for the treatment of locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) adenocarcinoma type in combination with docetaxel for the treatment of adult patients after the failure of first-line chemotherapy.